1-9 of 9
alkanesulfonates
Close
Sort by
Journal Articles

Factor VIII Plays a Direct Role in Osteoblast Development

Emily Ann Larson, BS, Jason A Taylor, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3661.
https://doi.org/10.1182/blood.V130.Suppl_1.3661.3661
Published: 2017
Journal Articles

Heparin-Induced Thrombocytopenia Antibody Testing and Its Cost Effectiveness: Taking a Financial HIT

Anusiyanthan Isaac Mariampillai, MD, Josephine Pineda Dela Cruz, MD, Harry Staszewski, MD, Nina D'Abreo, MD
Journal: Blood
Blood (2016) 128 (22): 2343.
https://doi.org/10.1182/blood.V128.22.2343.2343
Published: 2016
Journal Articles

Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)

Francesco Passamonti, MD, Martin Griesshammer, MD, Michele Cavo, MD, Miklos Egyed, MDPhD Prof., Giulia Benevolo, MD, Timothy Devos, MDPhD, Jeannie Callum, MD, Alessandro M. Vannucchi, MD, Serdar Sivgin, MD, Caroline Bensasson, PhD, Mahmudul Khan, PhD, Nadjat Mounedji, MD, Guray Saydam, MD Prof
Journal: Blood
Blood (2015) 126 (23): 2807.
https://doi.org/10.1182/blood.V126.23.2807.2807
Published: 2015
Journal Articles

Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder

Theodore E. Warkentin, MD, Paul Andrew Basciano, MD, Richard A. Bernstein, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 2328.
https://doi.org/10.1182/blood.V122.21.2328.2328
Published: 2013
Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4071.
https://doi.org/10.1182/blood.V122.21.4071.4071
Published: 2013
Journal Articles

Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications.

Jawed Fareed, PhD, Margaret Prechel, Ph.D., Michelle Kujawski, Ph.D., He Zhu, Ph.D., Jeanine Walenga, Ph.D., Debra Hoppensteadt, Ph.D., Josephine Cunanan, M.D., Renu Saxena, M.D.
Journal: Blood
Blood (2007) 110 (11): 3206.
https://doi.org/10.1182/blood.V110.11.3206.3206
Published: 2007
Journal Articles

A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.

Resmi Ravindran, PhD, Imran Khan, Ph.D., Robert Gosselin, Ted Wun, M.D, V.V. Krishnan, Ph.D., Paul Luciw, Ph.D., Kim Janatpour, M.D
Journal: Blood
Blood (2007) 110 (11): 3216.
https://doi.org/10.1182/blood.V110.11.3216.3216
Published: 2007
Journal Articles

Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).

Theodore E. Warkentin, MD, Richard M. Jay, MD, Michael Makris, MD, John G. Kelton, MD
Journal: Blood
Blood (2006) 108 (11): 1047.
https://doi.org/10.1182/blood.V108.11.1047.1047
Published: 2006
Journal Articles

Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.

Juan I. Luengo, Kevin J. Duffy, Anthony N. Shaw, Evelyne Delorme, Kenneth J. Wiggall, Leslie Giampa, Nannan Liu, Heather Smith, Shin-Shay Tian, Stephen G. Miller, Richard M. Keenan, Jon Rosen, Susan B. Dillon, Peter Lamb, Connie L. Erickson-Miller
Journal: Blood
Blood (2004) 104 (11): 2910.
https://doi.org/10.1182/blood.V104.11.2910.2910
Published: 2004